HTGM — HTG Molecular Diagnostics, Inc.

HTG Molecular Diagnostics, Inc. (HTGM) 是一家 Medical - Diagnostics & Research 公司，属于医疗保健行业, 目前交易价格为 $0.48. 其SharesGrow评分为 23/100, 表明较弱的投资特征， 7项中通过1项.

分析师共识目标价为 HTGM = $0 (-65.3% 上涨空间).

财务数据: 营收为 $6M, -26.6%/yr 平均增长. 净利润为 $22M (亏损), 增长率为 -5.4%/yr. 净利润率为 -339.2% (负值). 毛利率为 28.2% (-25.4 pp 趋势).

资产负债表: 总债务为 $5M 对比 $5M 股东权益 (D/E比率 0.9, 适度). 流动比率为 1.89 (流动性强). 资产负债率为 27.2%. 总资产: $18M.

分析师展望: 8 / 8 位分析师评级 HTGM 为买入 (100%) — 强烈共识.

SharesGrow 7项标准细分: Value 10/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 50/100 (Partial), Moat 14/100 (Fail), Future 64/100 (Pass), Income 10/100 (Fail).

$0.17

▼ 64.58% 下跌空间

平均目标价

The 12-month price target for HTG Molecular Diagnostics, Inc. is $0.17.

HTGM SharesGrow 评分概览

27/100

SharesGrow Score

Below average — proceed with caution

View full scorecard →

价值 10/100

估值 — P/E, PEG, Forward PEG

成长 15/100

财务数据 — 平均增长

过去 0/100

强劲 — 趋势

健康 50/100

资产负债表 — D/E比率, 流动比率为

护城河 14/100

毛利率为 + market cap

未來 64/100

分析师展望 — 为买入

收入 10/100

净利润率为

Scores derived from financial statements, analyst ratings, and balance sheet data.

评分明细 — HTGM

✗

价值 Fail

10/100

HTGM 市盈率(P/E)为 N/A (S&P 500平均约25). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + 上涨空间 (25%) + trailing PEG (20%). ≥ 60 = Pass.

HTGM: -26.6%/yr 营收为, -5.4%/yr 净利润为平均增长. 较弱. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

No analyst coverage available for this stock.

~

健康 Partial

50/100

资产负债表 HTGM: D/E比率 0.9 (适度), 流动比率为 1.89 (流动性强). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

HTGM: 毛利率为 28.2% (-25.4 pp 趋势), N/A market cap. Moat (0-100): margin (35%) + 趋势 (15%) + market cap (30%) + 营收为 (20%). Score 14/100. ≥ 70 = Pass.

分析师展望: 8 / 8 位分析师评级 HTGM 为买入 (100%). Score: 60% buy consensus + 40% 上涨空间. ≥ 60 = Pass.

HTGM: 净利润率为 -339.2%. 负值. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

股票图表与统计

市场数据

52周区间0.462-24.96

成交量725.43K

30日平均成交量253.92K

市值$1.06M

Beta（1年）0.99

股份统计

EPS（TTM）-24.28

流通股数$889.28K

IPO日期2015-05-06

员工数53

首席执行官John L. Lubniewski

财务亮点与比率

营收（TTM）$6.37M

毛利润$1.79M

EBITDA$-20.14M

净利润$-21.59M

营业利润$-20.83M

现金总额$12.21M

总负债$4.83M

净负债$-7.38M

总资产$17.78M

市盈率（P/E）-0

市销率（P/S）0.17

分析师预测

1年目标价$0.17

目标高位$0.17

目标低位$0.17

上涨空间-65.3%

评级共识Buy

覆盖分析师数8

买入 100% 持有 0% 卖出 0%

公司信息

国家US

交易所NASDAQ Capital Marke

货币USD

ISINUS40434H1041

股价走势

HTGM

HTG Molecular Diagnostics, Inc. ↗ · NASDAQ Capital Marke

Healthcare • Medical - Diagnostics & Research

0.46 52周区间 24.96

其他人也在看

GTH

Genetron Holdings Limited

$4.03

+0.12%

GENE

Genetic Technologies Limited

Psychemedics Corporation

$2.67

+100.00%

BIAF

bioAffinity Technologies, Inc.

$2.93

+4.27%

IDXG

Interpace Biosciences, Inc.

Intelligent Bio Solutions Inc.

$2.78

+0.36%

HTG Molecular Diagnostics, Inc. HTGM NASDAQ

HTGM SharesGrow 评分概览

评分明细 — HTGM

股票图表与统计

股价走势

其他人也在看

获取低估股票提醒